Pure Global
NCT06403709

Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients

Phase II Study of Irinotecan Plus Trifluridine/Tipiracil (TAS-102) in Combination With Bevacizumab as a Third-Line or Beyond Therapy for Patients With Metastatic Colorectal Cancer (mCRC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences·Phase 2·ClinicalTrials.gov·drugRecruitment Completed
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Metastatic Colorectal Cancer
Drug/Device/Intervention
Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Location
Beijing, China
Timeline & enrollment
Phase
Phase 2
Start date
Aug 01, 2022
End date
Aug 01, 2026
Enrollment
35 participants
Primary outcome

Objective Response Rate (ORR)

Summary

Currently, the approved third-line treatments for metastatic colorectal cancer (mCRC) include
 regorafenib, fruquintinib, and trifluridine/tipiracil(TAS-102). In recent years, several
 phase I/II studies evaluated the combination of TAS-102 and bevacizumab in mCRC patients who
 were refractory to standard therapies and showed promising antitumor efficacy and manageable
 toxicity. In this single-center phase II study, the investigators explored the efficacy and
 safety of irinotecan, TAS-102, plus bevacizumab in a third-line or beyond therapy for
 patients with mCRC.

ICD-10 classifications
Malignant neoplasm of colonMalignant neoplasm: Colon, unspecifiedMalignant neoplasm: Descending colonMalignant neoplasm: Ascending colonMalignant neoplasm: Overlapping lesion of colon
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06403709
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06403709 through Pure Global AI's free database. This Phase 2 trial is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences and is currently Recruitment Completed. The study focuses on Metastatic Colorectal Cancer. Target enrollment is 35 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.